Recombinant CD22 (Epratuzumab Biosimilar) antibody

Catalog No. ABIN7795108

This anti-CD22 (Epratuzumab Biosimilar) antibody is a Humanized Monoclonal antibody detecting CD22 (Epratuzumab Biosimilar) in FACS and in vivo. Suitable for Human.

Quick Overview for Recombinant CD22 (Epratuzumab Biosimilar) antibody (ABIN7795108)

Target: CD22 (Epratuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This CD22 (Epratuzumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CD22 (Epratuzumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Epratuzumab Biosimilar, Endotoxin 0.05 EU/mg

Characteristics: Epratuzumab Biosimilar uses the same protein sequences as the therapeutic antibody epratuzumab. Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus. Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: Less than 0.5 EU/mg of protein as determined by LAL method

Immunogen: Human CD22

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CD22 (Epratuzumab Biosimilar)

Target: CD22 (Epratuzumab Biosimilar)

Alternative Name: Epratuzumab Biosimilar

Target Type: Biosimilar